Head-to-head · 2026
WegovyvsOzempic
Top pick
Wegovy
Semaglutide
Score8.4/10
vs
Ozempic
Semaglutide
Score8.3/10
The short answer
Wegovy edges out Ozempic in our scoring, 8.4/10 versus 8.3/10. Wegovy (Semaglutide) and Ozempic (Semaglutide) are both GLP-1 receptor agonists; the gap comes from differences in efficacy data, cost, and access. Neither is universally better — the right choice depends on your insurance, diagnosis, and tolerance.
The key difference
Ozempic vs Wegovy: what actually differs
Ozempic and Wegovy are the same molecule — semaglutide — from the same maker, Novo Nordisk. The difference is the FDA-approved indication and dose: Ozempic is approved for type 2 diabetes at 0.5–2.0 mg weekly, while Wegovy is approved for chronic weight management at a higher 2.4 mg weekly dose.
Boxed warning (class-wide for GLP-1s): risk of thyroid C-cell tumors. Contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
| Attribute | Ozempic | Wegovy |
|---|---|---|
| FDA indication | Type 2 diabetes FDA label | Chronic weight management FDA label |
| Max dose (weekly SC) | 2.0 mg FDA label | 2.4 mg FDA label |
| High-dose option (weight mgmt) | None Ozempic is T2D-only; caps at 2.0 mg | 7.2 mg Wegovy HD (FDA Mar 2026): 20.6% at 72 wk vs 14.9% on 2.4 mg |
| On-label weight loss | No on-label endpoint Ozempic is T2D-indicated; weight loss is off-label | 14.9 % |
| CV outcome (MACE RRR) | 26 % | 20 % |
| HbA1c reduction (diabetes) | 1.5–1.8 % SUSTAIN program (on-label T2D) | Not an endpoint Weight-indicated; A1C off-label |
| Retail cash price | $997/mo Retail cash | $1,349/mo Retail cash |
| Rx status | Rx only FDA | Rx only FDA |
Side effects compared — incidence
| Effect | Ozempic | Wegovy |
|---|---|---|
| Nausea | 20% | 44% |
| Vomiting | 9% | 24% |
| Diarrhea | 9% | 30% |
| Constipation | 5% | 24% |
FDA prescribing-info baselines. Lower is better (green).
Choose Ozempic if
- You have type 2 diabetes — Ozempic is the on-label, insurance-covered choice and Medicare Part D covers it for T2D (Wegovy for weight loss is excluded).
- You want a lower retail price ($997 vs $1,349/mo cash) for the same molecule, and your goal is glycemic control with weight loss as a secondary benefit.
- Your priority is the documented 26% MACE reduction in established T2D + high CV risk (SUSTAIN 6).
Choose Wegovy if
- Your goal is weight loss without diabetes — Wegovy is the only one of the two FDA-approved for chronic weight management, with 14.9% mean loss at 68 weeks (STEP 1).
- You need the higher 2.4 mg dose; Ozempic tops out at 2.0 mg and cannot be titrated to the Wegovy weight-management target on-label.
- You have established cardiovascular disease without diabetes — Wegovy carries the SELECT label (20% MACE reduction) that Ozempic does not.
Switching between Ozempic & Wegovy
Switching between Ozempic and Wegovy is a dose conversion, not a different drug — both are semaglutide. A prescriber maps your current weekly dose to the nearest dose on the other product and usually restarts titration to manage GI tolerance; they are not interchangeable at the pharmacy (different pens, indications, and max doses). The usual reasons to switch: insurance (Ozempic is covered for type 2 diabetes) or needing the higher 2.4 mg weight-management dose (Wegovy).
Independently sourced from the cited trials; last verified June 2026. Editorial summary, not medical advice — see our methodology and editorial standards.
The verdict
Why Wegovy ranks first
Wegovy scores 8.4/10 vs Ozempic at 8.3/10. Detailed breakdown below.
- Top pick1#1· Editor's ChoiceEditor's ChoiceBest for CV Risk
FDA-approved semaglutide for chronic weight management
- Average 15% weight loss in clinical trials (STEP 1)
- FDA-approved with extensive safety record
- Weekly dosing
FDA-approvedBrand-nameOnce-weekly injectionGLP-1 receptor agonistInsurance eligibleMost transparent pricing8.4/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 2.4mg - 2Runner-up
Semaglutide approved for type 2 diabetes
- Strong A1C reduction in T2D
- Often covered by insurance for diabetes indication
Off-label useOnce-weekly injectionGLP-1 receptor agonistInsurance eligible8.3/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 1mg
Winners per category
Editorial pick
Ozempic
Highest combined score across six axes. Semaglutide approved for type 2 diabetes
8.3
/10
- Most effectiveWegovyScore: 9.5/10
- Best valueOzempicScore: 6.0/10
- Safest profileWegovyScore: 8.5/10
- Easiest accessOzempicScore: 7.0/10
- Most trustedWegovyScore: 9.5/10
Score comparison
Side-by-side scoring breakdown
WegovyOzempic
Effectiveness
0 — 10
Wegovy
9.5
Ozempic
9.0
Safety
0 — 10
Wegovy
8.5
Ozempic
8.5
Value
0 — 10
Wegovy
5.0
Ozempic
6.0
Accessibility
0 — 10
Wegovy
6.0
Ozempic
7.0
User experience
0 — 10
Wegovy
7.5
Ozempic
7.5
Trust
0 — 10
Wegovy
9.5
Ozempic
9.0
Side-by-side specs
| # | Product | Active ingredient | Starting price | True cost · maint. | FDA status | Score | |
|---|---|---|---|---|---|---|---|
| 1 | Wegovy Most transparent pricing | Semaglutide | $1349/mo | Best ·$499/mo · 2.4mg | approved | Top ·8.4 | View → |
| 2 | Ozempic | Semaglutide | Best ·$997/mo | Best ·$499/mo · 1mg | off-label | 8.3 | View → |
Effectiveness: Wegovy vs Ozempic
Wegovy (Semaglutide) and Ozempic (Semaglutide) both belong to the GLP-1 receptor agonist class, but their molecular structure and dosing differ enough to produce different real-world outcomes. Head-to-head trial data is limited; most comparisons come from cross-trial analysis of pivotal studies (STEP-1, SURMOUNT-1, SELECT, SUSTAIN).
On weight loss, Wegovy typically shows stronger placebo-adjusted reductions at 68 weeks, with greater proportions of patients reaching ≥15% body-weight loss. For type 2 diabetes patients, A1C reduction tends to track with the drug's underlying glucose-handling mechanism — single-agonist semaglutide compounds (Wegovy, Ozempic, Rybelsus) yield ~1.5% A1C drop, while dual GIP/GLP-1 agonists (Mounjaro, Zepbound) frequently exceed 2.0%.
Tolerability
Side effects: what to expect
GI side effects dominate the first 8-12 weeks of GLP-1 therapy regardless of which drug you start on. Nausea (35-45%), diarrhea (15-25%), constipation (15-20%), vomiting (10-15%), and headache (10-15%) are the most reported. Wegovy and Ozempic share this profile; the difference is usually in titration aggressiveness and individual tolerance, not the drug itself.
More serious but rare adverse events — pancreatitis, gallbladder disease, kidney injury during dehydration, and the boxed warning for medullary thyroid cancer in rodent models — apply to the entire GLP-1 class. If you have a personal or family history of MTC or MEN2, neither Wegovy nor Ozempic is appropriate. Talk to your prescribing physician about your risk profile before starting either.
Cost & access
Cost & insurance
Without insurance coverage, both Wegovy and Ozempic run between $1,000 and $1,400 per month at list price. Coverage decisions hinge on whether your plan treats the drug as a weight-loss medication (often excluded from formulary) or a diabetes medication (typically covered). Medicare Part D specifically excludes weight-loss indications under current rules, so a Wegovy prescription is denied even though Ozempic (same molecule) is covered for T2D — a gap that drives many switching decisions.
Manufacturer savings cards can lower out-of-pocket cost to as little as $25-$650/month for commercially insured patients depending on plan tier. If you're uninsured or your plan rejects coverage, compounded semaglutide and tirzepatide from licensed 503A/503B pharmacies are typically 60-80% cheaper but carry quality-variability and supply-chain risks that brand drugs don't.
Who it's for
Which one fits you
Who should choose Wegovy?
- You prioritize the strongest available weight-loss data and your insurance covers it, or you're willing to pay out of pocket via savings card.
- You have a cardiovascular risk profile that benefits from the trial evidence supporting this drug's class indication.
- Your prescriber is familiar with the titration schedule and your plan's prior authorization workflow.
Who should choose Ozempic?
- You prefer the alternative active ingredient based on tolerability, availability in your area, or insurance coverage.
- You had difficulty with prior Wegovy side effects and want to try a different molecule.
- Your prescribing clinic stocks it, has experience with its titration, or your pharmacy shows lower wait times.
If you're already on one
Switching between them
Switching from Wegovy to Ozempic (or vice versa) is generally straightforward but requires a careful titration restart, not a direct dose swap. Your prescriber will typically pause for 1 week, then begin the new drug at its lowest dose regardless of where you were on the original. This minimizes GI side effects from a full-strength reintroduction. Expect 4-12 weeks before reaching the maintenance dose on the new medication.
Reasons people switch include: insurance formulary changes, shortage of the original drug, intolerable side effects, plateauing weight loss, or moving from a single-agonist to a dual-agonist compound. The choice should always go through your prescribing physician — do not self-switch using compounded products without medical supervision.
Bottom line
Wegovy is our pick — but the deciding factor is yours
Wegovy is our editorial pick in this matchup with an overall score of 8.4/10, edging out Ozempic at 8.3/10. The score reflects a weighted average of clinical efficacy, safety profile, cost transparency, and access — not just trial outcomes. For most patients comparing these two, insurance coverage and pharmacy access will outweigh the scoring differential. Verify both with your prescriber and plan before committing.
From the brief
Recent editorial coverage
May 12, 2026· #018
TrumpRx adds Lilly. Zepbound now $549 direct.
Eli Lilly joins TrumpRx with Zepbound + Mounjaro at $549/mo cash. Plus: FDA Q1 enforcement actions, Hims settlement aftermath, and three new compounders we are watching.
Read issue →May 5, 2026· #017
FDA declares Wegovy shortage officially over.
The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
Read issue →Apr 28, 2026· #016
CMS finalizes Wegovy obesity coverage. PA still required.
Medicare Part D will cover Wegovy for obesity starting July 1, 2026 — but with strict prior auth. We obtained the draft PA criteria and cross-checked every line against the published rule.
Read issue →